Blood-based diagnostics of Alzheimer’s disease

References

• Alzheimer A. Über einen eigenartigen schweren Erkrankungsprozeβ der Hirnrincle. Neurol Cent. 1906;25:1134.
   Google Scholar
• Jack CR Jr, Bennett DA, Blennow K, et al. NIA-AA research framework: toward a biological definition of Alzheimer’s disease. Alzheimers Dement. 2018;14(4):535–562.
   PubMed Web of Science ®Google Scholar
• Dekker LJ, Burgers PC, Charif H, et al. Differential expression of protease activity in serum samples of prostate carcinoma patients with metastases. Proteomics. 2010 Jun;10(12):2348–2358.
   PubMed Web of Science ®Google Scholar
• Tamkovich S, Bryzgunova O. Protease activity and cell-free DNA in blood plasma of healthy donors and breast cancer patients. J Immunoassay Immunochem. 2016;37(2):141–153.
   PubMedGoogle Scholar
• Freudenberg-Hua Y, Li W, Davies P. The role of genetics in advancing precision medicine for Alzheimer’s disease-a narrative review. Front Med (Lausanne). 2018 Apr 24;5: 108.
   PubMed Web of Science ®Google Scholar
• Escott-Price V, Shoai M, Pither R, et al. Polygenic score prediction captures nearly all common genetic risk for Alzheimer’s disease. Neurobiol Aging. 2016;4:214e7–214e1116.
   Google Scholar
• Escott-Price V, Myers AJ, Huentelman M, et al. Polygenic risk score analysis of pathologically confirmed Alzheimer disease. Ann Neurol. 2017;82(2):311–314.
   PubMed Web of Science ®Google Scholar
• Falek and Chiarelli. Meiotic chromosome of man. P19-22 in meiosis research III. New York (NY): MSS Information Corporation; 1972. Melynk, John, Published.
   Google Scholar
• Poduslo SE, Huang R, Huang J, et al. Genome screen of late-onset Alzheimer’s extended pedigrees identifies TRPC4AP by haplotype analysis. Am J Med Genet B Neuropsychiatr Genet. 2009 Jan 5;150B(1):50–55.
   PubMed Web of Science ®Google Scholar
• Kienzl E, Jellinger K, Janetzky B, et al. A broader horizon of Alzheimer pathogenesis: ALZAS - an early serum biomarker. J Neural Transm Suppl. Vol 109, 2002;87–95.
   PubMedGoogle Scholar
• Jellinger KA, Janetzky B, Attems J, et al. Biomarkers for early diagnosis of Alzheimer disease: ‘ALZheimer ASsociated gene’–a new blood biomarker? J Cell Mol Med. 2008;12(4):1094–1117.
   PubMed Web of Science ®Google Scholar
• Idda ML, Munk R, Abdelmohsen K, et al. Noncoding RNAs in Alzheimer’s disease. Wiley Interdiscip Rev RNA. 2018 Mar;9(2):e1463.
   Web of Science ®Google Scholar
• Graham SF, Chevallier OP, Elliott CT, et al. Untargeted metabolomic analysis of human plasma indicates differentially affected polyamine and l-arginine metabolism in mild cognitive impairment subjects converting to Alzheimer’s disease. PLoS One. 2015.
   Web of Science ®Google Scholar
• Vural H, Sirin B, Yilmaz N, et al. The role of arginine-nitric oxide pathway in patients with Alzheimer disease. Biol Trace Elem Res. 2009 Summer;129(1–3):58–64.
   PubMed Web of Science ®Google Scholar
• Nakamura A, Kaneko N, Villemagne VL, et al. High performance plasma amyloid-β biomarkers for Alzheimer’s disease. Nature. 2018 Feb 8;554(7691):249–254. Epub 2018 Jan 31.
   PubMed Web of Science ®Google Scholar
• Thijssen E, Verberk IMW, Vanderstichele HM, et al. A prototype Simoa assay quantifying plasma amyloid beta 1-42 and 1-40 isoforms can differentiate participants with AD from healthy control subjects. Alzheimer’s Dementia. 2018; 14(7):P1039.
   Google Scholar
• Ovod V, Ramsey KN, Mawuenyega KG, et al. Amyloid β concentrations and stable isotope labeling kinetics of human plasma specific to central nervous system amyloidosis. Alzheimer’s Dementia. 2017. DOI:10.1016/j.jalz.2017.06.2266
   PubMed Web of Science ®Google Scholar
• Molinuevo JL, Ayton S, Batrla R, et al. Current state of Alzheimer’s fluid biomarkers. Acta Neuropathol. 2018 Nov 28. DOI:10.1007/s00401-018-1932-x.
   PubMed Web of Science ®Google Scholar
• Hampel H, O’Bryant SE, Molinuevo JL, et al. Blood-based biomarkers for Alzheimer disease: mapping the road to the clinic. Nat Rev Neurol. 2018 Nov;14(11):639–652.
   PubMed Web of Science ®Google Scholar
• O’Bryant SE, Mielke MM, Rissman RA, et al. Biofluid based biomarker professional interest area. Blood-based biomarkers in Alzheimer disease: current state of the science and a novel collaborative paradigm for advancing from discovery to clinic. Alzheimer’s Dementia. 2017 Jan;13(1):45–58.
   PubMed Web of Science ®Google Scholar
• Henriksen K, O’Bryant SE, Hampel H, et al. Blood-based biomarker interest group. The future of blood-based biomarkers for Alzheimer’s disease. Alzheimer’s Dementia. 2014 Jan;10(1):115–131.
   PubMed Web of Science ®Google Scholar
• Lista S, Faltraco F, Prvulovic D, et al. Blood and plasma-based proteomic biomarker research in Alzheimer’s disease. Prog Neurobiol. 2013 Feb-Mar;101-102:1–17.
   PubMed Web of Science ®Google Scholar
• Hampel H, Frank R, Broich K, et al. Biomarkers for Alzheimer’s disease: academic, industry and regulatory perspectives. Nat Rev Drug Discov. 2010 Jul;9(7):560–574.
   PubMed Web of Science ®Google Scholar
• Blennow K, Hampel H, Weiner M, et al. Cerebrospinal fluid and plasma biomarkers in Alzheimer disease. Nat Rev Neurol. 2010 Mar 6;(3): 131–144. DOI:10.1038/nrneurol.2010.4
   PubMed Web of Science ®Google Scholar
• With sudden progress, blood Aβ rivals PET at detecting amyloid; https://www.alzforum.org/news/conference-coverage/sudden-progress-blood-av-rivals-pet-detecting-amyloid, accessed December 10, 2018.
   Google Scholar
• Ponomarenko, Elena A., Poverennaya, Ekaterina V., Ilgisonis, Ekaterina V., et al. The size of the human proteome: the width and depth. Int J Anal Chem. Volume 2016; 6. Article ID 7436849.
   Web of Science ®Google Scholar
• Guo L-H, Alexopoulos P, Wagenpfeil S, et al. Plasma proteomics for the identification of Alzheimer disease. Alzheimer Dis Assoc Disord. 2013;27(4):337–342.
   PubMed Web of Science ®Google Scholar
• Hye A, Lynham S, Thambisetty M, et al. Proteome-based plasma biomarkers for Alzheimer’s disease. Brain. 2006 November 1;129(11):3042–3050.
   PubMedGoogle Scholar
• Lecocq S., Spinella K., Dubois B., et al. Aptamers as biomarkers for neurological disorders. Proof of concept in transgenic mice. PLoS One. 2018 Jan 5. DOI:10.1371/journal.pone.0190212.
   PubMed Web of Science ®Google Scholar
• Markley JL, Brüschweiler R, Edison AS, et al. The future of NMR-based metabolomics. Curr Opin Biotechnol. 2017 Feb;43:34–40.
   PubMed Web of Science ®Google Scholar
• Lopez MF, Mikulskis A, Kuzdzal S, et al. High-resolution serum proteomic profiling of Alzheimer disease samples reveals disease-specific, carrier-protein-bound mass signatures. Clin Chem. 2005;51(10):1946–1954.
   PubMed Web of Science ®Google Scholar
• Wishart DS, Jewison T, Guo AC, et al. HMDB 3.0 — the human metabolome database in 2013. Nucleic Acids Res. 2013 Jan 1;41(D1):D801–7.
   PubMed Web of Science ®Google Scholar
• Wilkins JM, Trushina E. Application of metabolomics in Alzheimer’s disease. Nucleic Acids Res. 2013 Jan;41(Database issue):D801–7. Frontiers in Neurology vol. 8 719. 12 Jan. 2018.
   PubMedGoogle Scholar
• Delpassand Ebrahim S, Chari Mohan V, Stager Charles E, et al. Rapid identification of common human pathogens by high resolution proton magnetic resonance spectroscopy. J Clin Microbiol. 1995 May; 33(5):1258–1262.
   PubMed Web of Science ®Google Scholar
• Penner G., Soizic L., Chopin A., et al. Novel use of aptamer libraries for prediction of amyloid status from blood serum. Poster LBP26, JPAD. 2018;5(4):S171–172.
   Google Scholar